Background:Resistin is a polypeptide hormone secreted by adipose tissue. A prior hospital-based case-control study reported serum resistin levels to be inversely associated with risk of multiple myeloma (MM). To date, this association has not been investigated prospectively.Methods:We measured resistin concentrations for pre-diagnosis peripheral blood samples from 178 MM cases and 358 individually matched controls from three cohorts participating in the MM cohort consortium.Results:In overall analyses, higher resistin levels were weakly associated with reduced MM risk. For men, we observed a statistically significant inverse association between resistin levels and MM (odds ratio, 0.44; 95% confidence interval (CI) 0.24-0.83 and 0.54; 95% CI 0.29-0.99, for the third and fourth quartiles, respectively, vs the lowest quartile; P trend =0.03). No association was observed for women.Conclusions:This study provides the first prospective evidence that low circulating resistin levels may be associated with an increased risk of MM, particularly for men.
CITATION STYLE
Santo, L., Teras, L. R., Giles, G. G., Weinstein, S. J., Albanes, D., Wang, Y., … Hofmann, J. N. (2017). Circulating resistin levels and risk of multiple myeloma in three prospective cohorts. British Journal of Cancer, 117(8), 1241–1245. https://doi.org/10.1038/bjc.2017.282
Mendeley helps you to discover research relevant for your work.